Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
18.62
+0.45 (2.48%)
At close: Aug 1, 2025, 4:00 PM
18.63
+0.01 (0.05%)
After-hours: Aug 1, 2025, 4:20 PM EDT
Innoviva Employees
Innoviva had 127 employees as of December 31, 2024. The number of employees increased by 15 or 13.39% compared to the previous year.
Employees
127
Change (1Y)
15
Growth (1Y)
13.39%
Revenue / Employee
$2,912,157
Profits / Employee
-$470,268
Market Cap
1.17B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 127 | 15 | 13.39% |
| Dec 31, 2023 | 112 | 11 | 10.89% |
| Dec 31, 2022 | 101 | 96 | 1,920.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | 5 | -1 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INVA News
- 7 weeks ago - FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 - Business Wire
- 7 weeks ago - Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults - Business Wire
- 2 months ago - Innoviva to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections - Business Wire
- 2 months ago - Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States - GlobeNewsWire
- 3 months ago - Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 5 months ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 5 months ago - Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference - Business Wire